Updated on 29 July 2015
BioNexus is a special status awarded to qualified international and Malaysian companies
Singapore: IndiPharm, a clinical development organization, headquartered in US, has been awarded BioNexus status from the Malaysian Biotechnology Corporation (Biotechcorp).
IndiPharm has operations in US, India and Malaysia and has relocated its Asian operations center to Kuala Lumpur in anticipation of future growth and client demands.
Mr Edward Brennan, president and CEO, IndiPharm stated, "IndiPharm is excited to have received the BioNexus status. Aside from the financial incentives provided, the Bionexus status grants IndiPharm access to clients and markets that otherwise would not be possible. We look forward to a long and successful relationship with Malaysian Biotechnology Corporation as we continue to expand our presence in Malaysia and Asia."
BioNexus is a special status awarded to qualified international and Malaysian companies undertaking value-added biotechnology and/or life sciences activities in Malaysia. The status endows fiscal incentives, grants, and other guarantees to assist growth.
Dr Mohd Nazlee Kamal, chief executive officer, Malaysian Biotechnology Corporation said, "We are very pleased for IndiPharm to join the list of BioNexus status companies, especially as they have chosen to establish their Asian headquarters in Malaysia. IndiPharm's vast knowledge and expertise in clinical research services will undoubtedly enrich the growth of the biomedical sector in Malaysia, particularly in conducting clinical trials. We hope IndiPharm will take full advantage of the benefits that the BioNexus status offers to contribute to the healthcare community."